Breast Cancer Research and Treatment

, Volume 134, Issue 3, pp 1291–1295 | Cite as

Association of sleep duration and breast cancer OncotypeDX recurrence score

Epidemiology

Abstract

Shorter duration of sleep has been associated with risk of a number of medical conditions, including breast cancer. However, no prior study has investigated the relationship of average sleep duration before diagnosis and cancer aggressiveness. OncotypeDX is a widely utilized test to guide treatment in early stage hormone receptor positive breast cancer by predicting likelihood of recurrence. We reviewed medical records from ER+ early stage breast cancer patients participating in a case–control study for availability of OncotypeDX scores. All patients in the parent study were recruited at diagnosis and asked about average sleep duration in the 2 years before diagnosis. We analyzed data from 101 breast cancer patients with available OncotypeDX recurrence scores to test the hypothesis that shorter sleep is associated with greater likelihood of recurrence. We found that OncotypeDX recurrence scores were strongly correlated with average hours of sleep per night before breast cancer diagnosis, with fewer hours of sleep associated with a higher (worse) recurrence score (R = −0.30, p = 0.0031). This correlation was limited to post-menopausal breast cancer patients only (R = −0.41, p = 0.0011, for postmenopausal patients; R = −0.05, p = 0.80 for pre-menopausal patients). This association remains statistically significant after adjustment for age, physical activity, smoking status, and body mass index in the entire study sample (p = 0.0058) as well as in postmenopausal patients (p = 0.0021). This is the first study to suggest that women who routinely sleep fewer hours may develop more aggressive breast cancers compared with women who sleep longer hours.

Keywords

Breast cancer OncotypeDX Sleep Recurrence 

References

  1. 1.
    Thompson CL et al (2011) Short duration of sleep increases risk of colorectal adenoma. Cancer 117(4):841–847PubMedCrossRefGoogle Scholar
  2. 2.
    Verkasalo PK et al (2005) Sleep duration and breast cancer: a prospective cohort study. Cancer Res 65(20):9595–9600PubMedCrossRefGoogle Scholar
  3. 3.
    Wu AH et al (2008) Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis 29(6):1244–1248PubMedCrossRefGoogle Scholar
  4. 4.
    Kakizaki M et al (2008) Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer 99(9):1502–1505PubMedCrossRefGoogle Scholar
  5. 5.
    Pinheiro SP et al (2006) A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. Cancer Res 66(10):5521–5525PubMedCrossRefGoogle Scholar
  6. 6.
    Paik S et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826PubMedCrossRefGoogle Scholar
  7. 7.
    Paik S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734PubMedCrossRefGoogle Scholar
  8. 8.
    Patel SR, Hu FB (2008) Short sleep duration and weight gain: a systematic review. Obesity (Silver Spring) 16(3):643–653CrossRefGoogle Scholar
  9. 9.
    Hsu CM et al (2012) Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumour Biol 33(1):149–155PubMedCrossRefGoogle Scholar
  10. 10.
    Sato F et al (2011) PERIOD1 (PER1) has anti-apoptotic effects, and PER3 has pro-apoptotic effects during cisplatin (CDDP) treatment in human gingival cancer CA9-22 cells. Eur J Cancer 47(11):1747–1758PubMedCrossRefGoogle Scholar
  11. 11.
    Climent J et al (2011) Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol 28(23):3770–3778CrossRefGoogle Scholar
  12. 12.
    Blask DE (2009) Melatonin, sleep disturbance and cancer risk. Sleep Med Rev 13(4):257–264PubMedCrossRefGoogle Scholar
  13. 13.
    Stevens RG (2005) Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology 16(2):254–258PubMedCrossRefGoogle Scholar
  14. 14.
    Collis SJ, Boulton SJ (2007) Emerging links between the biological clock and the DNA damage response. Chromosoma 116(4):331–339PubMedCrossRefGoogle Scholar
  15. 15.
    Hoffman AE et al (2008) The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res 6(9):1461–1468PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  1. 1.Department of Family Medicine and Community Health, Case Comprehensive Cancer Center Case Western Reserve UniversityClevelandUSA

Personalised recommendations